The new pig on the block: Modelling cancer in pigs

Transgenic Research

Volumn 22, Issue 4, 2013, Pages 673-680

  Flisikowska, Tatiana ^a   Kind, Alexander ^a   Schnieke, Angelika ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

APC; Cancer; Disease model; Gene targeting; p53; Swine

Indexed keywords

APC PROTEIN; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL; DISEASE MODEL; GENETIC ENGINEERING; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATION; NEOPLASM; PATHOLOGY; REVIEW;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; MICE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880426860     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11248-013-9720-9     Document Type: Review

References (56)

1. Adam SJ, Rund LA, Kuzmuk KN, Zachary JF, Schook LB, Counter CM (2007) Genetic induction of tumorigenesis in swine. Oncogene 26: 1038-1045.
2. Anderson LJ, Jarrett WFH (1968) Lymphosarcoma (Leukemia) in cattle, sheep and pigs in Great Britain. Cancer 22: 398-405.
3. Bendixen E, Danielsen M, Larsen K, Bendixen C (2010) Advances in porcine genomics and proteomics-a toolbox for developing the pig as a model organism for molecular biomedical research. Brief Funct Genomics 9: 208-219.
4. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, Pitot HC, Halberg RB, Itzkowitz SH, Groden J, Coffey RJ (2003) Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124: 762-777.
5. Borovansky J, Horak V, Elleder M, Fortyna K, Smit NP, Kolb AM (2003) Biochemical characterization of a new melanoma model-the minipig MeLiM strain. Melanoma Res 13: 543-548.
6. Brown DG, Johnson DF (1970) Diseases of aged swine. J Am Vet Med Assoc 157: 1914-1918.
7. Carlson DF, Tan W, Lillico SG, Stverakova D, Proudfoot C, Christian M, Voytas DF, Long CR, Whitelaw CB, Fahrenkrug SC (2012) Efficient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci USA 109: 17382-17387.
8. Croner RS, Brueckl WM, Reingruber B, Hohenberger W, Guenther K (2005) Age and manifestation related symptoms in familial adenomatous polyposis. BMC Cancer 5: 24.
9. Dai Y, Vaught TD, Boone J, Chen SH, Phelps CJ, Ball S, Monahan JA, Jobst PM, McCreath KJ, Lamborn AE, Cowell-Lucero JL, Wells KD, Colman A, Polejaeva IA, Ayares DL (2002) Targeted disruption of the alpha1, 3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 20: 251-255.
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). GLOBOCAN 2008 v1. 2, Cancer Incidence and Mortality worldwide. in IARC CancerBase, vol. 10. International Agency for Research on Cancer. Lyon, France.
11. Fisher LF, Olander HJ (1978) Spontaneous neoplasm of pigs-a study of 31 cases. J Comp Path. 88: 505-517.
12. Flisikowska T, Thorey IS, Offner S, Ros F, Lifke V, Zeitler B, Rottmann O, Vincent A, Zhang L, Jenkins S, Niersbach H, Kind AJ, Gregory PD, Schnieke AE, Platzer J (2011) Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. PLoS ONE 6: e21045. doi: 10. 1371/journal. pone. 0021045.
13. Flisikowska T, Merkl C, Landmann M, Eser S, Rezaei N, Cui X, Kurome M, Zakhartchenko V, Kessler B, Wieland H, Rottmann O, Schmid RM, Schneider G, Kind A, Wolf E, Saur D, Schnieke A (2012) A porcine model of familial adenomatous polyposis. Gastroenterology 143: 1173-1175.
14. Frese KK, Tuveson DA (2007) Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658.
15. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
16. Goh AM, Coffill CR, Lane DP (2011) The role of mutant p53 in human cancer. J Pathol 223: 116-126.
17. Greene JF Jr, Morgan CD, Rao A, Amoss MS Jr, Arguello F (1997) Regression by differentiation in the Sinclair swine model of cutaneous melanoma. Melanoma Res 7: 471-477.
18. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M et al (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589-600.
19. Groenen MAM, Archibald AL, Uenishi H, Tuggle CK, Takeuchi Y, Rothschild MF et al (2012) Analyses of pig genomes provide insight into porcine demography and evolution. Nature 491: 393-398.
20. Guilbault C, Saeed Z, Downey GP, Radzioch D (2007) Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36: 1-7.
21. Hidalgo J, Belani J, Maxwell K, Lieber D, Talcott M, Baron P, Ames C, Venkatesh R, Landman J (2005) Development of exophytic tumor model for laparoscopic partial nephrectomy: technique and initial experience. Urology 65: 872-876.
22. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483.
23. Hooper ML (1998) Tumour suppressor gene mutations in humans and mice: parallels and contrasts. EMBO J 17: 6783-6789.
24. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis, Chen HS, Feuer EJ, Cronin KA, Edwards BK (2011) SEER cancer statistics review, 1975-2008. In: Surveillance Epidemiology and End Results. National Cancer Institute, Bethesda, MD.
25. Huang G, Tong C, Kumbhani DS, Ashton C, Yan H, Ying QL (2011) Beyond knockout rats: new insights into finer genome manipulation in rats. Cell Cycle 10: 1059-1066.
26. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S et al (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
27. Kaitin KI (2010) Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Therapeut 87: 356-361.
28. Kendall SD, Linardic CM, Adam SJ, Counter CM (2005) A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res 65: 9824-9828.
29. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253: 661-665.
30. Leuchs S, Saalfrank A, Merkl C, Flisikowska T, Edlinger M, Durkovic M, Rezaei N, Kurome M, Zakhartchenko V, Kessler B, Flisikowski K, Kind A, Wolf E, Schnieke A (2012) Inactivation and inducible oncogenic mutation of p53 in gene targeted pigs. PLoS ONE 7: e43323. doi: 10. 1371/journal. pone. 0043323.
31. Li X, Zhou X, Guan Y, Wang YX, Scutt D, Gong QY (2006) N-nitrosodiethylamine-induced pig liver hepatocellular carcinoma model: radiological and histopathological studies. Cardiovasc Intervent Radiol 29: 420-428.
32. Luo Y, Bolund L, Sorensen CB (2011) High efficiency of BRACA1 knockout using rAAV-mediated gene targeting: developing a pig model for breast cancer. Transgenic Res 20: 975-988.
33. Martignoni M, Groothuis GM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2: 875-894.
34. McCalla-Martin AC, Chen X, Linder KE, Estrada JL, Piedrahita JA (2010) Varying phenotypes in swine versus murine transgenic models constitutively expressing the same human Sonic hedgehog transcriptional activator, K5-HGLI2 Delta N. Transgenic Res 19: 869-887.
35. McCreath KJ, Howcroft J, Campbell KH, Colman A, Schnieke AE, Kind AJ (2000) Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature 405: 1066-1069.
36. Midgley CA, Lane DP (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189.
37. Mittra J, Tait J (2012) Analysing stratified medicine business models and value systems: innovation-regulation interactions. N Biotechnol 15: 709-719.
38. Mussolino C, Cathomen T (2013) RNA guides genome engineering. Nat Biotechnol 31: 208-209.
39. N'Djin WA, Melodelima D, Parmentier H, Rivoire M, Chapelon JY (2007) A tumor-mimic model for evaluating the accuracy of HIFU preclinical studies: an in vivo study. Conf Proc IEEE Eng Med Biol Soc 2007: 3544-3547.
40. Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10: 428-438.
41. Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156.
42. Pathak S, Multani AS, McConkey DJ, Imam AS, Amoss MS (2000) Spontaneous regression of cutaneous melanoma in Sinclair swine is associated with defective telomerase activity and extensive telomere erosion. Int J Oncol 17: 1219-1224.
43. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237.
44. Rangarajan A, Hong SJ, Gifford A, Weinberg RA (2004) Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6: 171-183.
45. Renner S, Braun-Reichhart C, Blutke A, Herbach N, Emrich D, Streckel E, Wünsch A, Kessler B, Kurome M, Bähr A, Klymiuk N, Krebs S, Puk O, Nagashima H, Graw J, Blum H, Wanke R, Wolf E (2013) Permanent neonatal diabetes in INSC94Y transgenic pigs. Diabetes 62: 1505-1511.
46. Scharek L, Tedin K (2007) The porcine immune system-differences compared to man and mouse and possible consequences for infections by Salmonella serovars. Berl Munch Tierarztl Wochenschr 120: 347-354.
47. Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M, Wilmut I, Colman A, Campbell KH (1997) Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 278: 2130-2133.
48. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12: 278-287.
49. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Weihong Xu et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110: 3507-3512.
50. Stevenson RG, DeWitt WF (1973) An unusual case of lymphosarcoma in a pig. Can Vet 14: 139-141.
51. Swindle MM (2007). Swine in the laboratory: Surgery, anesthesia, imaging, and experimental techniques. Pub CRC press, Boca Raton, FL, USA.
52. van Boxtel R, Kuiper RV, Toonen PW, van Heesch S, Hermsen R et al (2011) Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency. Am J Pathol 179: 1616-1622.
53. Vargo-Gogola T, Rosen JM (2007) Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7: 659-672.
54. Vincent-Naulleau S, Le Chalony C, Leplat JJ, Bouet S, Bailly C, Spatz A, Vielh P, Avril MF, Tricaud Y, Gruand J, Horak V, Frelat G, Geffrotin C (2004) Clinical and histopathological characterization of cutaneous melanomas in the melanoblastoma-bearing Libechov minipig model. Pigment Cell Res 17: 24-35.
55. Yamakawa H, Nagai T, Harasawa R, Yamagami T, Takahashi J, Ishikawa K-I, Nomura N, Nagashima H (1999) Production of transgenic pig carrying MMTV/v-Ha-ras. J Reprod Dev 45: 111-118.
56. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.